English
Insider transactions
EDGARWhitehawk Therapeutics, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-20.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 14 transactions, 705,358 shares
- Sum of shares × price per share: 2,584,560.1888
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 70
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-15 Filed 2026-09-18 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 193,957 | 0 | — | 193,957 | Direct (D) | No | F1
| Open filing 0001995275-26-000018 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-18 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 193,957 | 0 | — | 193,957 | Direct (D) | No | F2, F3
| Open filing 0001995275-26-000018 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-18 | Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 118,476 | 0 | — | 118,476 | Direct (D) | No | F1
| Open filing 0001754154-26-000016 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-18 | Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 118,476 | 0 | — | 118,476 | Direct (D) | No | F2, F3
| Open filing 0001754154-26-000016 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-18 | BALL BRYAN Officer: See remarks | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 91,633 | 0 | — | 91,633 | Direct (D) | No | F1
| Open filing 0001766522-26-000017 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-18 | BALL BRYAN Officer: See remarks | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 91,633 | 0 | — | 91,633 | Direct (D) | No | F2, F3
| Open filing 0001766522-26-000017 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-18 | Dornan David Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 85,887 | 0 | — | 85,887 | Direct (D) | No | F1
| Open filing 0001821353-26-000007 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-18 | Dornan David Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 85,887 | 0 | — | 85,887 | Direct (D) | No | F2, F3
| Open filing 0001821353-26-000007 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-18 | Dugan Margaret Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 81,250 | 0 | — | 81,250 | Direct (D) | No | F1
| Open filing 0001909734-26-000011 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-18 | Dugan Margaret Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 81,250 | 0 | — | 81,250 | Direct (D) | No | F2, F3
| Open filing 0001909734-26-000011 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-15 | Dugan Margaret Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 81,250 | 0 | — | 81,250 | Direct (D) | No | F1
| Open filing 0001909734-26-000009 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-15 | Dugan Margaret Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 81,250 | 0 | — | 81,250 | Direct (D) | No | F2, F3
| Open filing 0001909734-26-000009 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-15 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 193,957 | 0 | — | 193,957 | Direct (D) | No | F1
| Open filing 0001995275-26-000016 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-15 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 193,957 | 0 | — | 193,957 | Direct (D) | No | F2, F3
| Open filing 0001995275-26-000016 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-15 | Dornan David Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 85,887 | 0 | — | 85,887 | Direct (D) | No | F1
| Open filing 0001821353-26-000005 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-15 | Dornan David Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 85,887 | 0 | — | 85,887 | Direct (D) | No | F2, F3
| Open filing 0001821353-26-000005 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-15 | Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 118,476 | 0 | — | 118,476 | Direct (D) | No | F1
| Open filing 0001754154-26-000014 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-15 | Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 118,476 | 0 | — | 118,476 | Direct (D) | No | F2, F3
| Open filing 0001754154-26-000014 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-15 | BALL BRYAN Officer: See remarks | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 91,633 | 0 | — | 91,633 | Direct (D) | No | F1
| Open filing 0001766522-26-000015 Read from the filing’s XML Dispute this row |
| 2026-09-15 Filed 2026-09-15 | BALL BRYAN Officer: See remarks | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 91,633 | 0 | — | 91,633 | Direct (D) | No | F2, F3
| Open filing 0001766522-26-000015 Read from the filing’s XML Dispute this row |
| 2026-09-09 Filed 2026-09-11 | Iyengar Vijay K Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 76,080 | 0 | — | 76,080 | Direct (D) | No | F1
| Open filing 0001670000-26-000008 Read from the filing’s XML Dispute this row |
| 2026-06-12 Filed 2026-07-30 | Dalal Anupam Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,040 | 0 | — | 38,040 | Direct (D) | No | F2
| Open filing 0001602474-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-12 Filed 2026-06-15 | Maroun Richard E Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,040 | 0 | — | 38,040 | Direct (D) | No | F1
| Open filing 0001364590-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-12 Filed 2026-06-15 | Castelein Caley Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,040 | 0 | — | 38,040 | Direct (D) | No | F1
| Open filing 0001355758-26-000007 Read from the filing’s XML Dispute this row |
| 2026-06-12 Filed 2026-06-15 | Hirmand Mohammad Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,040 | 0 | — | 38,040 | Direct (D) | No | F1
| Open filing 0001654482-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-12 Filed 2026-06-15 | Aghazadeh Behzad Director · 10% owner · Other: See remarksAvoro Capital Advisors LLC Director · 10% owner · Other: See remarksAvoro Ventures LLC Director · 10% owner · Other: See remarks | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,040 | 0 | — | 38,040 | Direct (D) | No | F1, F2, F3
| Open filing 0001701815-26-000006 Read from the filing’s XML Dispute this row |
| 2026-06-12 Filed 2026-06-15 | Zhao Baiteng Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,040 | 0 | — | 38,040 | Direct (D) | No | F1
| Open filing 0002049287-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-12 Filed 2026-06-15 | Desai Neil Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,040 | 0 | — | 38,040 | Direct (D) | No | F1
| Open filing 0001878692-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-12 Filed 2026-06-15 | Reeve Emma Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,040 | 0 | — | 38,040 | Direct (D) | No | F1
| Open filing 0001680329-26-000005 Read from the filing’s XML Dispute this row |
| 2026-05-14 Filed 2026-07-30 | Dalal Anupam Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 1,275,510 | 3.92 | 4,999,999.2Derived: shares × price per share. Exact value 4999999.20. | 4,685,912 | Indirect (I) See footnote | No | F1
| Open filing 0001602474-26-000004 Read from the filing’s XML Dispute this row |
| 2026-05-14 Filed 2026-05-18 | Castelein Caley Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 255,102 | 3.92 | 999,999.84Derived: shares × price per share. Exact value 999999.84. | 274,796 | Direct (D) | No | — | Open filing 0001355758-26-000003 Read from the filing’s XML Dispute this row |
| 2026-05-14 Filed 2026-05-18 | Castelein Caley Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,072,756 | 8,124,996.24 | 16,841,134,706,437.44Derived: shares × price per share. Exact value 16841134706437.44. | 2,072,756 | Indirect (I) See footnote | No | F2, F3
| Open filing 0001355758-26-000003 Read from the filing’s XML Dispute this row |
| 2026-05-14 Filed 2026-05-18 | BALL BRYAN Officer: See remarks | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 51,020 | 3.92 | 199,998.4Derived: shares × price per share. Exact value 199998.40. | 448,126 | Direct (D) | No | — | Open filing 0001766522-26-000013 Read from the filing’s XML Dispute this row |
| 2026-05-14 Filed 2026-05-18 | Dugan Margaret Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 19,132 | 3.92 | 74,997.44Derived: shares × price per share. Exact value 74997.44. | 19,132 | Direct (D) | No | — | Open filing 0001909734-26-000005 Read from the filing’s XML Dispute this row |
| 2026-05-14 Filed 2026-05-18 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 51,021 | 3.92 | 200,002.32Derived: shares × price per share. Exact value 200002.32. | 569,643 | Direct (D) | No | — | Open filing 0001995275-26-000014 Read from the filing’s XML Dispute this row |
| 2026-05-14 Filed 2026-05-18 | Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,265 | 3.92 | 149,998.8Derived: shares × price per share. Exact value 149998.80. | 333,489 | Direct (D) | No | — | Open filing 0001754154-26-000012 Read from the filing’s XML Dispute this row |
| 2026-05-12 Filed 2026-05-14 | Avoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · 10% owner · Other: See Remarks | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,377,714 | 3.9199 | 25,000,001.1086Derived: shares × price per share. Exact value 25000001.1086. | 14,710,714 | Indirect (I) See footnotes | No | F1, F2, F3, F4
| Open filing 0000902664-26-002449 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-17 | Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 141,600 | 4.13 | 584,808Derived: shares × price per share. Exact value 584808.00. | 295,224 | Direct (D) | No | F1
| Open filing 0001754154-26-000010 Read from the filing’s XML Dispute this row |
| 2026-04-15 Filed 2026-04-17 | Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 77,000 | 3.86 | 297,220Derived: shares × price per share. Exact value 297220.00. | 436,824 | Direct (D) | No | F1, F2
| Open filing 0001754154-26-000010 Read from the filing’s XML Dispute this row |
| 2026-04-14 Filed 2026-04-15 | BALL BRYAN Officer: See remarks | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 92,460 | 3.64 | 336,554.4Derived: shares × price per share. Exact value 336554.40. | 397,106 | Direct (D) | No | F1
| Open filing 0001766522-26-000011 Read from the filing’s XML Dispute this row |
| 2026-04-13 Filed 2026-04-15 | BALL BRYAN Officer: See remarks | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 26,389 | 3.46 | 91,305.94Derived: shares × price per share. Exact value 91305.94. | 489,566 | Direct (D) | No | F1
| Open filing 0001766522-26-000011 Read from the filing’s XML Dispute this row |
| 2026-04-10 Filed 2026-04-13 | BALL BRYAN Officer: See remarks | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 6,596 | 3.43 | 22,624.28Derived: shares × price per share. Exact value 22624.28. | 515,955 | Direct (D) | No | F1
| Open filing 0001766522-26-000009 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | BALL BRYAN Officer: See remarks | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 50,000 | 3.57 | 178,500Derived: shares × price per share. Exact value 178500.00. | 522,551 | Direct (D) | No | F1
| Open filing 0001766522-26-000009 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-10 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 14,500 | 3.38 | 49,010Derived: shares × price per share. Exact value 49010.00. | 518,622 | Direct (D) | No | F1
| Open filing 0001995275-26-000012 Read from the filing’s XML Dispute this row |
| 2026-04-08 Filed 2026-04-08 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 63,945 | 3.4 | 217,413Derived: shares × price per share. Exact value 217413.0. | 533,122 | Direct (D) | No | F1
| Open filing 0001995275-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-07 Filed 2026-04-08 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 94,087 | 3.43 | 322,718.41Derived: shares × price per share. Exact value 322718.41. | 597,067 | Direct (D) | No | F1
| Open filing 0001995275-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-06 Filed 2026-04-08 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 102,395 | 3.51 | 359,406.45Derived: shares × price per share. Exact value 359406.45. | 691,154 | Direct (D) | No | F1
| Open filing 0001995275-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-02 Filed 2026-04-03 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 26,858 | 3.48 | 93,465.84Derived: shares × price per share. Exact value 93465.84. | 793,549 | Direct (D) | No | F2
| Open filing 0001995275-26-000006 Read from the filing’s XML Dispute this row |
| 2026-04-01 Filed 2026-04-03 | Dugan Margaret Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 283,157 | 0 | — | 283,157 | Direct (D) | No | F1
| Open filing 0001909734-26-000003 Read from the filing’s XML Dispute this row |
| 2026-04-01 Filed 2026-04-03 | Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 775,828 | — | — | 820,407 | Direct (D) | No | F1
| Open filing 0001995275-26-000006 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.
Showing 1–50 of 92
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| Yu Fan | 4,829,398 SH | 18,158,536 dollars | Lower by 31,916 Prior quarter: 4,861,314 | Open filing 0001193125-26-463618 Filed 2026-11-16 Dispute this row |
| ACUTA CAPITAL PARTNERS, LLC | 4,685,912 SH | 17,619,029 dollars | Unchanged Prior quarter: 4,685,912 | Open filing 0001104659-26-127905 Filed 2026-11-16 Dispute this row |
| QVT Financial LP | 4,615,709 SH | 15,619,559 dollars | Unchanged Prior quarter: 4,615,709 | Open filing 0001193125-26-463263 Filed 2026-11-16 Dispute this row |
| MONTANOVA CAPITAL, LLC | 4,170,875 SH | 15,682,490 dollars | Lower by 129,125 Prior quarter: 4,300,000 | Open filing 0001172661-26-005325 Filed 2026-11-16 Dispute this row |
| ORBIMED ADVISORS LLC | 3,853,472 SH | 14,489,055 dollars | Lower by 80,824 Prior quarter: 3,934,296 | Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row |
| Avoro Capital Advisors LLC | 2,849,402 SH | 10,713,752 dollars | Unchanged Prior quarter: 2,849,402 | Open filing 0001104659-26-127608 Filed 2026-11-16 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 2,589,723 SH | 9,737,359 dollars | Higher by 666,895 Prior quarter: 1,922,828 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| Siren, L.L.C. Partly reported under another manager | 2,337,102 SH | 8,787,504 dollars | Unchanged Prior quarter: 2,337,102 | Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row |
| KVP Capital Advisors, LP | 2,165,997 SH | 8,144,149 dollars | Unchanged Prior quarter: 2,165,997 | Open filing 0001104659-26-127594 Filed 2026-11-16 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,465,827 SH | 5,511,510 dollars | Higher by 77,266 Prior quarter: 1,388,561 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| ADAR1 Capital Management, LLC | 1,341,394 SH | 5,043,641 dollars | Unchanged Prior quarter: 1,341,394 | Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 1,055,562 SH | 3,969,690 dollars | Higher by 155,782 Prior quarter: 899,780 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| ACORN CAPITAL ADVISORS, LLC | 932,139 SH | 3,504,843 dollars | Lower by 207,224 Prior quarter: 1,139,363 | Open filing 0001636587-26-000102 Filed 2026-11-16 Dispute this row |
| RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager | 663,922 SH | 2,496,347 dollars | Higher by 250,100 Prior quarter: 413,822 | Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 591,672 SH | 2,224,687 dollars | Higher by 204,690 Prior quarter: 386,982 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| TWO SIGMA INVESTMENTS, LP | 550,739 SH | 2,070,779 dollars | Higher by 254,127 Prior quarter: 296,612 | Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row |
| Woodline Partners LP | 507,061 SH | 1,906,549 dollars | Higher by 70,447 Prior quarter: 436,614 | Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row |
| STEMPOINT CAPITAL LP | 495,980 SH | 1,864,885 dollars | Lower by 525,057 Prior quarter: 1,021,037 | Open filing 0001420506-26-002774 Filed 2026-11-16 Dispute this row |
| MILLENNIUM MANAGEMENT LLC | 442,900 SH | 1,665,304 dollars | Higher by 62,494 Prior quarter: 380,406 | Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row |
| ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager | 436,226 SH | 1,635 dollars | Higher by 265,343 Prior quarter: 170,883 | Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 329,303 SH | 1,238,179 dollars | Higher by 64,614 Prior quarter: 264,689 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| Eversept Partners, LP | 303,171 SH | 1,139,923 dollars | Lower by 135 Prior quarter: 303,306 | Open filing 0001697013-26-000007 Filed 2026-11-16 Dispute this row |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 296,030 SH | 1,113,073 dollars | Higher by 76,813 Prior quarter: 219,217 | Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 283,605 SH | 1,066,355 dollars | Higher by 36,698 Prior quarter: 246,907 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| Squarepoint Ops LLC Partly reported under another manager | 206,513 SH | 776,489 dollars | Not in the prior quarter’s filings read | Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row |
| Qube Research Technologies Ltd | 197,064 SH | 740,961 dollars | Higher by 148,071 Prior quarter: 48,993 | Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row |
| GOLDMAN SACHS GROUP INC Partly reported under another manager | 196,509 SH | 738,874 dollars | Higher by 69,751 Prior quarter: 126,758 | Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row |
| Verdad Advisers, LP | 153,698 SH | 577,904 dollars | Lower by 147,785 Prior quarter: 301,483 | Open filing 0001420506-26-002833 Filed 2026-11-16 Dispute this row |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 115,284 SH | 433,468 dollars | Lower by 50,000 Prior quarter: 165,284 | Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 105,867 SH | 398,060 dollars | Higher by 27,035 Prior quarter: 78,832 | Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row |
| DIMENSIONAL FUND ADVISORS LP Partly reported under another manager | 105,011 SH | 394,682 dollars | Higher by 71,591 Prior quarter: 33,420 | Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row |
| Bank of New York Mellon Corp Partly reported under another manager | 98,416 SH | 370,044 dollars | Higher by 15,784 Prior quarter: 82,632 | Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row |
| UBS Group AG Partly reported under another manager | 78,502 SH | 295,167 dollars | Higher by 27,661 Prior quarter: 50,841 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| Integrated Quantitative Investments LLC | 75,846 SH | 285,181 dollars | Not in the prior quarter’s filings read | Open filing 0001941040-26-000818 Filed 2026-11-13 Dispute this row |
| Jump Financial, LLC Partly reported under another manager | 71,400 SH | 268,464 dollars | Higher by 30,600 Prior quarter: 40,800 | Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row |
| AMERICAN CENTURY COMPANIES INC Partly reported under another manager | 63,973 SH | 240,538 dollars | Higher by 12,133 Prior quarter: 51,840 | Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 63,133 SH | 237,380 dollars | Higher by 33,153 Prior quarter: 29,980 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| Nuveen, LLC Partly reported under another manager | 54,530 SH | 205,033 dollars | Higher by 10,731 Prior quarter: 43,799 | Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row |
| FMR LLC Partly reported under another manager | 43,933 SH | 165,188 dollars | Higher by 43,763 Prior quarter: 170 | Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row |
| Invesco Ltd. Partly reported under another manager | 43,888 SH | 165,020 dollars | Higher by 4,709 Prior quarter: 39,179 | Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row |
| HRT FINANCIAL LP | 43,614 SH | 163 dollars | Not in the prior quarter’s filings read | Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row |
| DEUTSCHE BANK AG\ Partly reported under another manager | 36,657 SH | 137,830 dollars | Higher by 4,989 Prior quarter: 31,668 | Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row |
| BANK OF AMERICA CORP /DE/ Partly reported under another manager | 35,726 SH | 134,330 dollars | Higher by 1,100 Prior quarter: 34,626 | Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row |
| XTX Topco Ltd Partly reported under another manager | 35,666 SH | 134,104 dollars | Higher by 17,144 Prior quarter: 18,522 | Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row |
| Susquehanna Portfolio Strategies, LLC | 29,148 SH | 109,596 dollars | Not in the prior quarter’s filings read | Open filing 0001996449-26-000009 Filed 2026-11-16 Dispute this row |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 28,380 SH | 106,709 dollars | Not in the prior quarter’s filings read | Open filing 0001177206-26-000010 Filed 2026-11-12 Dispute this row |
| PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager | 26,609 SH | 101 dollars | Unchanged Prior quarter: 26,609 | Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row |
| MetLife Investment Management, LLC Partly reported under another manager | 25,768 SH | 96,888 dollars | Not in the prior quarter’s filings read | Open filing 0001628280-26-073956 Filed 2026-11-16 Dispute this row |
| RHUMBLINE ADVISERS | 25,108 SH | 94,404 dollars | Higher by 579 Prior quarter: 24,529 | Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 22,913 SH | 86,153 dollars | Not in the prior quarter’s filings read | Open filing 0001085146-26-000916 Filed 2026-10-27 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Ally Bridge Group (NY) LLC 817,939 SH
- Balyasny Asset Management L.P. 288,117 SH
- Sixth Street Partners Management Company, L.P. 78,832 SH
- Y-Intercept (Hong Kong) Ltd 24,363 SH
- Virtu Financial LLC 14,479 SH
- Scientech Research LLC 10,838 SH
- Quadrature Capital Ltd 10,044 SH
- TWO SIGMA SECURITIES, LLC 10,033 SH
- Quarry LP 218 SH
- Integrated Wealth Concepts LLC 132 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Dellora Investments LP Common Stock, $0.0001 par value per share | 5.6 | 3,169,287.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G | Open filing 0001943462-26-000010 Dispute this row |
| Kevin Pyun Common Stock, $0.0001 par value per share | 5.6 | 3,169,287.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G | Open filing 0001943462-26-000010 Dispute this row |
| ABG Management Ltd. Common Stock, par value $0.0001 per share | 0 | 0.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001493152-26-052436 Dispute this row |
| Ally Bridge Group (NY) LLC Common Stock, par value $0.0001 per share | 0 | 0.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001493152-26-052436 Dispute this row |
| Ally Bridge MedAlpha Master Fund L.P. Common Stock, par value $0.0001 per share | 0 | 0.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001493152-26-052436 Dispute this row |
| ABG Global Life Science Capital Partners V GP Limited Common Stock, par value $0.0001 per share | 7.8 | 4,829,398.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001493152-26-052436 Dispute this row |
| ABG Global Life Science Capital Partners V GP, L.P. Common Stock, par value $0.0001 per share | 7.8 | 4,829,398.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001493152-26-052436 Dispute this row |
| Ally Bridge Group Global Life Science Capital Partners V, L.P. Common Stock, par value $0.0001 per share | 7.8 | 4,829,398.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001493152-26-052436 Dispute this row |
| ABG-SIV, L.P. Common Stock, par value $0.0001 per share | 7.8 | 4,829,398.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001493152-26-052436 Dispute this row |
| ABG V-SIV Limited Common Stock, par value $0.0001 per share | 7.8 | 4,829,398.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001493152-26-052436 Dispute this row |
| Fan Yu Common Stock, par value $0.0001 per share | 7.8 | 4,829,398.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001493152-26-052436 Dispute this row |
| Coastlands Capital LP Common Stock, par value $0.0001 per share | 6.19 | 3,653,440.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-127421 Dispute this row |
| Coastlands Capital Partners LP Common Stock, par value $0.0001 per share | 6.19 | 3,653,440.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-127421 Dispute this row |
| Coastlands Capital GP LLC Common Stock, par value $0.0001 per share | 6.19 | 3,653,440.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-127421 Dispute this row |
| Coastlands Capital LLC Common Stock, par value $0.0001 per share | 6.19 | 3,653,440.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-127421 Dispute this row |
| Matthew D. Perry Common Stock, par value $0.0001 per share | 6.19 | 3,653,440.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-127421 Dispute this row |
| OrbiMed Advisors LLC Common Stock, par value $0.0001 per share | 7.3 | 3,934,296.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0000947871-26-000805 Dispute this row |
| OrbiMed Genesis GP LLC Common Stock, par value $0.0001 per share | 7.3 | 3,934,296.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0000947871-26-000805 Dispute this row |
| ABG Management Ltd. Common Stock, par value $0.0001 per share | 1.4 | 817,939.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| Ally Bridge Group (NY) LLC Common Stock, par value $0.0001 per share | 1.4 | 817,939.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| Ally Bridge MedAlpha Master Fund L.P. Common Stock, par value $0.0001 per share | 1.4 | 817,939.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| ABG Innovation Capital Partners III GP Limited Common Stock, par value $0.0001 per share | 0 | 0.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| ABG Innovation Capital Partners III GP, L.P. Common Stock, par value $0.0001 per share | 0 | 0.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| Ally Bridge Group Innovation Capital Partners III, L.P. Common Stock, par value $0.0001 per share | 0 | 0.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| ABG Innovation-SO Limited Common Stock, par value $0.0001 per share | 0 | 0.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| ABG Global Life Science Capital Partners V GP Limited Common Stock, par value $0.0001 per share | 8.1 | 4,861,314.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| ABG Global Life Science Capital Partners V GP, L.P. Common Stock, par value $0.0001 per share | 8.1 | 4,861,314.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| Ally Bridge Group Global Life Science Capital Partners V, L.P. Common Stock, par value $0.0001 per share | 8.1 | 4,861,314.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| ABG-SIV, L.P. Common Stock, par value $0.0001 per share | 8.1 | 4,861,314.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| ABG V-SIV Limited Common Stock, par value $0.0001 per share | 8.1 | 4,861,314.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| Fan Yu Common Stock, par value $0.0001 per share | 9.4 | 5,679,253.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001493152-26-038432 Dispute this row |
| ACUTA CAPITAL PARTNERS, LLC Common Stock | 8.7 | 4,685,912.00 | 05/14/2026 Filed 2026-05-18 | SCHEDULE 13D/AAmendment 2 | Open filing 0000935836-26-000289 Dispute this row |
| ANUPAM DALAL Common Stock | 9.0 | 4,843,775.00 | 05/14/2026 Filed 2026-05-18 | SCHEDULE 13D/AAmendment 2 | Open filing 0000935836-26-000289 Dispute this row |
| Acuta Capital Fund, LP Common Stock | 6.6 | 3,538,288.00 | 05/14/2026 Filed 2026-05-18 | SCHEDULE 13D/AAmendment 2 | Open filing 0000935836-26-000289 Dispute this row |
| Avoro Capital Advisors LLC Common stock, par value $0.0001 per share | 19.99 | 15,893,516.00 | 05/12/2026 Filed 2026-05-14 | SCHEDULE 13D/AAmendment 5 | Open filing 0000902664-26-002450 Dispute this row |
| Avoro Ventures LLC Common stock, par value $0.0001 per share | 4.1 | 2,288,950.00 | 05/12/2026 Filed 2026-05-14 | SCHEDULE 13D/AAmendment 5 | Open filing 0000902664-26-002450 Dispute this row |
| Behzad Aghazadeh Common stock, par value $0.0001 per share | 19.99 | 18,292,675.00 | 05/12/2026 Filed 2026-05-14 | SCHEDULE 13D/AAmendment 5 | Open filing 0000902664-26-002450 Dispute this row |
| Coastlands Capital LP Common stock | 5.98 | 2,819,215.00 | 08/19/2025 Filed 2025-08-25 | SCHEDULE 13G | Open filing 0001172661-25-003766 Dispute this row |
| Coastlands Capital Partners LP Common stock | 5.98 | 2,819,215.00 | 08/19/2025 Filed 2025-08-25 | SCHEDULE 13G | Open filing 0001172661-25-003766 Dispute this row |
| Coastlands Capital GP LLC Common stock | 5.98 | 2,819,215.00 | 08/19/2025 Filed 2025-08-25 | SCHEDULE 13G | Open filing 0001172661-25-003766 Dispute this row |
| Coastlands Capital LLC Common stock | 5.98 | 2,819,215.00 | 08/19/2025 Filed 2025-08-25 | SCHEDULE 13G | Open filing 0001172661-25-003766 Dispute this row |
| Matthew D. Perry Common stock | 5.98 | 2,819,215.00 | 08/19/2025 Filed 2025-08-25 | SCHEDULE 13G | Open filing 0001172661-25-003766 Dispute this row |
| BML Investment Partners, L.P. Common stock, par value $0.0001 per share | 8.5 | 2,100,000 | 12/31/2024 Filed 2024-12-31 | SCHEDULE 13D | Open filing 0001373604-24-000118 Dispute this row |
| Leonard Braden Michael Common stock, par value $0.0001 per share | 9.9 | 2,435,000 | 12/31/2024 Filed 2024-12-31 | SCHEDULE 13D | Open filing 0001373604-24-000118 Dispute this row |
| AVORO CAPITAL ADVISORS LLC Common stock, par value $0.0001 per share | 11.6 | 2,849,402.00 | 12/19/2024 Filed 2024-12-23 | SCHEDULE 13D/AAmendment 3 | Open filing 0000902664-24-007000 Dispute this row |
| AVORO VENTURES LLC Common stock, par value $0.0001 per share | 2.5 | 622,350.00 | 12/19/2024 Filed 2024-12-23 | SCHEDULE 13D/AAmendment 3 | Open filing 0000902664-24-007000 Dispute this row |
| BEHZAD AGHAZADEH Common stock, par value $0.0001 per share | 14.5 | 3,581,961.00 | 12/19/2024 Filed 2024-12-23 | SCHEDULE 13D/AAmendment 3 | Open filing 0000902664-24-007000 Dispute this row |
| Neil Desai Common stock, par value $0.0001 per share | 9.2 | 2,263,566 | 12/19/2024 Filed 2024-12-23 | SCHEDULE 13D/AAmendment 3 | Open filing 0000950170-24-139724 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,550,114 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 17,857 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 176,407 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 262,403 |
Filings made before the SEC required XML are listed, not extracted.